{"id":57793,"date":"2024-02-27T18:00:17","date_gmt":"2024-02-27T18:00:17","guid":{"rendered":"https:\/\/medsname.com\/ivabrad\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"ivabrad","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/ivabrad\/","title":{"rendered":"Ivabrad"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Ivabrad?<\/h3>\n<p style=\"margin:0;\"><strong>Ivabrad<\/strong> is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer &mdash; a selective inhibitor of the <strong>I<sub>f<\/sub> (&#8220;funny&#8221;) current<\/strong> in the sinoatrial node. Ivabradine was introduced by Servier in 2005 as <strong>Procoralan<\/strong> &mdash; the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the I<sub>f<\/sub> current responsible for spontaneous SA node depolarisation. selectively blocks I<sub>f<\/sub> in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction &mdash; it is a &#8220;pure&#8221; bradycardia agent. Dosing: Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR &gt;60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (&gt;75 yr) start 2.5 mg twice daily. Arrhythmia management is a cardiology-led discipline &mdash; diagnosis, drug selection, and monitoring typically require specialist input. This is not a drug for self-initiated therapy.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Wat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde <a href=\"https:\/\/medsbase.com\/nl\/reviews\/\">klantbeoordelingen<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Elke bestelling is gedekt door onze <a href=\"https:\/\/medsbase.com\/nl\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n<h3>Waarom bestellen bij MedsBase<\/h3>\n<p>Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Ivabrad?<\/h2>\n<p>Ivabrad is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Ivabradine was introduced by Servier in 2005 as <strong>Procoralan<\/strong> &mdash; the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the I<sub>f<\/sub> current responsible for spontaneous SA node depolarisation.<\/p>\n<h2 class=\"wp-block-heading\">How Ivabradine Works<\/h2>\n<p>Ivabradine selectively blocks I<sub>f<\/sub> in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction &mdash; it is a &#8220;pure&#8221; bradycardia agent.<\/p>\n<h2 class=\"wp-block-heading\">Goedgekeurde Toepassingen<\/h2>\n<ul>\n<li><strong>Chronic symptomatic heart failure with reduced ejection fraction (HF-REF)<\/strong> &mdash; in patients with EF &le;35%, sinus rhythm, and heart rate &gt;70 bpm despite maximum-tolerated beta-blocker (or beta-blocker intolerance). <strong>SHIFT trial evidence.<\/strong><\/li>\n<li><strong>Chronische stabiele angina<\/strong> &mdash; add-on to beta-blocker or alone where beta-blockers are contraindicated. <strong>BEAUTIFUL and SIGNIFY trials.<\/strong><\/li>\n<li>Inappropriate sinus tachycardia (off-label)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dosering en Monitoring<\/h2>\n<p><strong>Dosering:<\/strong> Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR &gt;60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (&gt;75 yr) start 2.5 mg twice daily.<\/p>\n<p><strong>Monitoring:<\/strong><\/p>\n<ul>\n<li><strong>Uitgangswaarden:<\/strong> 12-lead ECG (confirm sinus rhythm, assess HR and QT), BP, U&amp;E.<\/li>\n<li><strong>2-4 weeks:<\/strong> HR review; titrate up or down.<\/li>\n<li><strong>Doorlopend:<\/strong> periodic HR and ECG; target resting HR 50-60 bpm in HF-REF.<\/li>\n<li><strong>Stop bij:<\/strong> symptomatic bradycardia (HR &lt;50 with symptoms), new AF (ivabradine efficacy is sinus-rhythm dependent), visual phenomena severe enough to affect driving\/work.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bijwerkingen<\/h2>\n<ul>\n<li><strong>Luminous phenomena (phosphenes)<\/strong> &mdash; transient enhanced brightness in peripheral vision (15%); usually improves spontaneously. Mechanism: ivabradine also weakly blocks I<sub>h<\/sub> current in retinal photoreceptors.<\/li>\n<li><strong>Bradycardie<\/strong> &mdash; dose-limiting (5-10%)<\/li>\n<li><strong>Atriumfibrilleren<\/strong> &mdash; modest excess vs placebo in trials; the drug is not effective once sinus rhythm is lost<\/li>\n<li><strong>Hoofdpijn, duizeligheid<\/strong><\/li>\n<li><strong>First-degree AV block, ventricular extrasystoles<\/strong><\/li>\n<li><strong>Huiduitslag<\/strong><\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Contra-indicaties<\/h2>\n<ul>\n<li>Resting HR &lt;70 bpm before starting<\/li>\n<li>Cardiogenic shock, acute MI<\/li>\n<li>Ernstige hypotensie<\/li>\n<li>Sick sinus syndrome, sinoatrial block, third-degree AV block without pacemaker<\/li>\n<li>Unstable or acute heart failure<\/li>\n<li>Atrial fibrillation (not effective; may worsen rate control)<\/li>\n<li>Pacemaker-dependent<\/li>\n<li>Ernstige leverfunctiestoornis<\/li>\n<li>Strong CYP3A4 inhibitor co-therapy<\/li>\n<li>Zwangerschap en borstvoeding<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Geneesmiddelinteracties<\/h2>\n<ul>\n<li><strong>Sterke CYP3A4-remmers \u2014 KRITIEK.<\/strong> Contraindicated: clarithromycin, itraconazole, ketoconazole, ritonavir, nefazodone, nelfinavir. Caution with moderate inhibitors (diltiazem, verapamil \u2014 note these also add bradycardia independently).<\/li>\n<li><strong>Diltiazem, verapamil<\/strong> &mdash; avoid (additive bradycardia + CYP3A4 inhibition).<\/li>\n<li><strong>QT-verlengende geneesmiddelen<\/strong> &mdash; caution; ivabradine has minimal intrinsic QT effect but combined risk rises.<\/li>\n<li><strong>Grapefruitsap<\/strong> &mdash; raises ivabradine levels.<\/li>\n<li><strong>B\u00e8tablokkers<\/strong> &mdash; combination is standard in HF-REF where beta-blocker alone is inadequate; watch for additive bradycardia.<\/li>\n<\/ul>\n<h2 id=\"faqs\">Veelgestelde vragen<\/h2>\n<h3 class=\"wp-block-heading\">What are the visual phosphenes?<\/h3>\n<p>About 15% of patients experience transient enhanced brightness in peripheral vision &mdash; particularly when looking from dim to bright light. They are benign (ivabradine weakly blocks a similar current in retinal photoreceptors) and usually adapt over weeks. Severe phenomena that affect driving or work are indication to stop.<\/p>\n<h3 class=\"wp-block-heading\">Can I take ivabradine if I have atrial fibrillation?<\/h3>\n<p>No &mdash; ivabradine only slows the sinoatrial node, so it has no effect on AF and may even make rate control worse. In AF use beta-blockers, non-DHP CCBs, or digoxin instead.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Ivabrad in pregnancy?<\/h3>\n<p>Generally no. Ivabradine has animal teratogenicity data; pregnancy is contraindicated in the licensed indications.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Ivabrad online?<\/h3>\n<p>You can buy Ivabrad (ivabradine 7.5 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Gerelateerde cardiovasculaire medicatie<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nl\/abana\/\">Abana \u2014 Ayurvedische cardiale formulering<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/aldactone\/\">Aldactone \u2014 Spironolacton<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/cardace\/\">Cardace \u2014 Ramipril (ACE-remmer)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/ecosprin\/\">Ecosprin \u2014 Aspirine 75\/150 mg (plaatjesremmer)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/lonitab\/\">Lonitab \u2014 Minoxidil 5 mg (orale vaatverwijder)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/vymada\/\">Vymada \u2014 Sacubitril\/Valsartan ARNI<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/high-blood-pressure-medication\/\"><strong>Bekijk alle hoge bloeddruk medicijnen<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Medisch disclaimer.<\/strong> Deze pagina is alleen voor informatieve doeleinden en vervangt geen medisch advies van een gekwalificeerde zorgverlener. Hypertensie, hartfalen en aritmie\u00ebn vereisen diagnose, monitoring en doseringsindividualisatie door een arts \u2014 gebruik b\u00e8tablokkers altijd onder medische begeleiding.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Gerelateerde alternatieven<\/h3>\n<p>Andere producten in <strong>Chronische aandoeningen<\/strong> die klanten ook bekijken:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nl\/prilox-cream\/\">Prilox Cream<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/rozucor\/\">Rozucor<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/lasix\/\">Lasix<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/meftal\/\">Meftal<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/carvego\/\">Carvego<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Ivabrad is ivabradine 7.5 mg tablets \u2014 the first selective I-f current inhibitor, acting at the sinoatrial node to slow heart rate without affecting blood pressure, contractility, or AV conduction. Originally Servier Procoralan (2005). SHIFT trial validated in HF-REF with HR >70 despite beta-blocker; BEAUTIFUL\/SIGNIFY extended evidence to chronic stable angina. Only effective in sinus rhythm \u2014 not for atrial fibrillation. Contraindicated with strong CYP3A4 inhibitors.<\/p>","protected":false},"featured_media":57794,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[4359,4360],"class_list":{"0":"post-57793","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-ivabrad","11":"product_tag-ivabradine","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/57793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=57793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/57794"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=57793"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=57793"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=57793"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=57793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}